journal
MENU ▼
Read by QxMD icon Read
search

Oncologist

journal
https://read.qxmd.com/read/30755503/can-peripherally-inserted-central-catheters-be-safely-placed-in-patients-with-cancer-receiving-chemotherapy-a-retrospective-study-of-almost-400-000-catheter-days
#1
Sara Campagna, Silvia Gonella, Paola Berchialla, Giacomo Morano, Carla Rigo, Pietro Antonio Zerla, Raffaella Fuzzi, Gianvito Corona, Silvana Storto, Valerio Dimonte, Baudolino Mussa
BACKGROUND: Peripherally inserted central catheters (PICCs) are central venous catheters (CVCs) that are commonly used in onco-hematologic settings for chemotherapy administration. As there is insufficient evidence to recommend a specific CVC for chemotherapy administration, we aimed to ascertain PICC-related adverse events (AEs) and identify independent predictors of PICC removal in patients with cancer receiving chemotherapy. MATERIALS AND METHODS: Information on adult patients with cancer with a PICC inserted for chemotherapy administration between September 2007 and December 2014 was extracted from six hospital databases...
February 12, 2019: Oncologist
https://read.qxmd.com/read/30755502/sidedness-matters-surrogate-biomarkers-prognosticate-colorectal-cancer-upon-anatomic-location
#2
Irit Ben-Aharon, Tal Goshen-Lago, Michal Sternschuss, Sara Morgenstern, Ravit Geva, Alexander Beny, Ygael Dror, Mariana Steiner, Ayala Hubert, Efraim Idelevich, Katerina Shulman, Moshe Mishaeli, Sophia Man, Nicky Liebermann, Lior Soussan-Gutman, Baruch Brenner
BACKGROUND: Anatomic location of primary tumors across the colon correlate with survival in the metastatic setting, whereas left-sided tumors may exhibit superior survival compared with right-sided tumors. The Oncotype Recurrence Score (RS) assay is a clinically validated predictor of recurrence risk in patients with stage II colorectal cancer (CRC). Previous studies had indicated that without adjuvant chemotherapy, CDX2-negative stage II CRC tumors are associated with a lower rate of disease-free survival than CDX2-positive stage II CRC tumors...
February 12, 2019: Oncologist
https://read.qxmd.com/read/30755501/a-case-of-donor-transmitted-non-small-cell-lung-cancer-after-liver-transplantation-an-unwelcome-guest
#3
Mohamad B Sonbol, Kevin C Halling, David D Douglas, Helen J Ross
Cancer transmission with organ donation has been previously reported with a variety of malignancies and organ transplants. The risk of transmission through organ transplantation from donors with a history of previously treated malignancies has been addressed by guidelines from transplant societies. Herein, we report a case of a patient who developed lung cancer confined to the liver after liver transplantation with no known history of malignancy in the donor. The suspicion of donor origin arose after positron emission tomography-computerized tomography scan showed metastatic lung cancer only involving the transplanted liver without a primary focus...
February 12, 2019: Oncologist
https://read.qxmd.com/read/30755500/high-ido1-expression-is-associated-with-poor-outcome-in-patients-with-anal-cancer-treated-with-definitive-chemoradiotherapy
#4
Devarati Mitra, Nora K Horick, Diane G Brackett, Kent W Mouw, Jason L Hornick, Soldano Ferrone, Theodore S Hong, Harvey Mamon, Jeffrey W Clark, Aparna R Parikh, Jill N Allen, David P Ryan, David T Ting, Vikram Deshpande, Jennifer Y Wo
BACKGROUND: This study characterizes the tumor-immune microenvironment in pretreatment, localized anal squamous cell carcinoma (ASCC), including two markers that have not previously been studied in ASCC: indoleamine 2,3 dioxygenase 1 (IDO1) and human leukocyte antigen (HLA) class I. MATERIALS AND METHODS: Retrospective review identified 63 patients with ASCC receiving definitive chemoradiation between 2005 and 2016 with pretreatment tissue available. Immunohistochemistry was used to quantify cluster of differentiation 8 (CD8), programmed cell death protein 1, programmed death-ligand 1, HLA class I, and IDO1...
February 12, 2019: Oncologist
https://read.qxmd.com/read/30728278/feasibility-assessment-of-using-the-complete-patient-reported-outcomes-version-of-the-common-terminology-criteria-for-adverse-events-pro-ctcae-item-library
#5
Daniel Shepshelovich, Kate McDonald, Anna Spreafico, Albiruni R A Razak, Philippe L Bedard, Lillian L Siu, Lori Minasian, Aaron R Hansen
The patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) complements capture of symptomatic adverse events (AEs) by clinicians. Previous trials have typically used a limited subset of relevant symptomatic AEs to reduce patient burden. We aimed to determine the feasibility of administering all 80 AEs included in the PRO-CTCAE library by approaching consecutive patients enrolled in a large academic phase I program at three points in time. Here, we report a preplanned analysis after enrolling the first 20 patients...
February 6, 2019: Oncologist
https://read.qxmd.com/read/30728277/efficacy-of-split-schedule-versus-conventional-schedule-neoadjuvant-cisplatin-based-chemotherapy-for-muscle-invasive-bladder-cancer
#6
Chelsea K Osterman, Dilip S Babu, Daniel M Geynisman, Bianca Lewis, Robert A Somer, Arjun V Balar, Matthew R Zibelman, Elizabeth A Guancial, Gianna Antinori, Shun Yu, Vivek Narayan, Thomas J Guzzo, Elizabeth R Plimack, David J Vaughn, Chunkit Fung, Ronac Mamtani
Neoadjuvant cisplatin-based chemotherapy (NAC; 70 mg/m2 ) is standard of care for muscle-invasive bladder carcinoma (MIBC). Many patients (pts) cannot receive cisplatin because of renal impairment, and administration of cisplatin 35 mg/m2 on day 1 + 8 or 1 + 2 (i.e., split schedule) is a commonly used alternative. In this retrospective analysis, we compared complete (pT0) and partial (<pT2) pathologic response rates between split schedule (SS) and conventional schedule (CS) pts, after 1:1 matching on chemotherapy regimen, number of cycles, tumor histology, and clinical stage...
February 6, 2019: Oncologist
https://read.qxmd.com/read/30728276/evaluating-the-strength-of-the-association-between-industry-payments-and-prescribing-practices-in-oncology
#7
Aaron P Mitchell, Aaron N Winn, Jennifer L Lund, Stacie B Dusetzina
BACKGROUND: Financial relationships between physicians and the pharmaceutical industry are common, but factors that may determine whether such relationships result in physician practice changes are unknown. MATERIALS AND METHODS: We evaluated physician use of orally administered cancer drugs for four cancers: prostate (abiraterone, enzalutamide), renal cell (axitinib, everolimus, pazopanib, sorafenib, sunitinib), lung (afatinib, erlotinib), and chronic myeloid leukemia (CML; dasatinib, imatinib, nilotinib)...
February 6, 2019: Oncologist
https://read.qxmd.com/read/30710068/neoadjuvant-management-of-early-breast-cancer-a-clinical-and-investigational-position-statement
#8
Ramon Colomer, Cristina Saura, Pedro Sánchez-Rovira, Tomás Pascual, Isabel T Rubio, Octavio Burgués, Lourdes Marcos, César A Rodríguez, Miguel Martín, Ana Lluch
BACKGROUND: Neoadjuvant treatment is increasingly one of the preferred therapeutic options for early breast cancer and may have some unique outcomes, such as identifying predictive and prognostic factors of response or increasing the knowledge of individual tumor biology. DESIGN: A panel of experts from different specialties reviewed published clinical studies on the neoadjuvant management of breast cancer. Recommendations were made that emphasized the clinical multidisciplinary management and the investigational leverage in early breast cancer...
February 1, 2019: Oncologist
https://read.qxmd.com/read/30710067/a-pilot-study-of-vinorelbine-safety-and-pharmacokinetics-in-patients-with-varying-degrees-of-liver-dysfunction
#9
Jun Gong, May Cho, Rohan Gupta, Timothy W Synold, Paul Frankel, Christopher Ruel, Marwan Fakih, Vincent Chung, Dean Lim, Joseph Chao
BACKGROUND: Vinorelbine has demonstrated anticancer activity and is primarily metabolized in the liver. This single-institution, phase I pilot study describes the safety and pharmacokinetics of vinorelbine in patients with varying degrees of hepatic impairment. MATERIALS AND METHODS: Patients with treatment-refractory solid tumors were enrolled into treatment arms based on vinorelbine dose (weekly infusions of 7.5-30 mg/m2 ) and liver function (normal liver function, mild, moderate, or severe liver dysfunction)...
February 1, 2019: Oncologist
https://read.qxmd.com/read/30710066/a-cost-effectiveness-analysis-of-nivolumab-and-ipilimumab-versus-sunitinib-in-first-line-intermediate-to-poor-risk-advanced-renal-cell-carcinoma
#10
Daniel Reinhorn, Michal Sarfaty, Moshe Leshno, Assaf Moore, Victoria Neiman, Eli Rosenbaum, Daniel A Goldstein
BACKGROUND: The treatment paradigm of advanced renal cell carcinoma (RCC) has changed rapidly in recent years. In first-line treatment of intermediate- to poor-risk patients, the CheckMate 214 study demonstrated a significant survival advantage for nivolumab and ipilimumab versus sunitinib. The high cost of combined immune-modulating agents warrants an understanding of the combination's value by considering both efficacy and cost. The objective of this study was to estimate the cost-effectiveness of nivolumab and ipilimumab compared with sunitinib for first-line treatment of intermediate- to poor-risk advanced RCC from the U...
February 1, 2019: Oncologist
https://read.qxmd.com/read/30710065/changes-in-the-use-of-comprehensive-geriatric-assessment-in-clinical-trials-for-older-patients-with-cancer-over-time
#11
Olivia Le Saux, Claire Falandry, Hui K Gan, Benoit You, Gilles Freyer, Julien Péron
BACKGROUND: The objective of this study was to describe the implementation of comprehensive geriatric assessment (CGA) in clinical trials dedicated to older patients before and after the creation of the International Society of Geriatric Oncology in the early 2000s. SUBJECTS, MATERIALS, AND METHODS: All phase I, II, and III trials dedicated to the treatment of cancer among older patients published between 2001 and 2004 and between 2011 and 2014 were reviewed. We considered that a CGA was performed when the authors indicated an intention to do so in the Methods section of the article...
February 1, 2019: Oncologist
https://read.qxmd.com/read/30696724/m1b-disease-in-the-8th-edition-of-tnm-staging-of-lung-cancer-pattern-of-single-extrathoracic-metastasis-and-clinical-outcome
#12
Hyesun Park, Suzanne E Dahlberg, Christine A Lydon, Tetsuro Araki, Hiroto Hatabu, Michael S Rabin, Bruce E Johnson, Mizuki Nishino
BACKGROUND: The 8th edition of TNM staging of non-small cell lung cancer (NSCLC) has revised M classification and defined M1b disease with single extrathoracic metastasis, which is distinguished from M1c with multiple extrathoracic metastases. We investigated the prevalence, characteristics, and overall survival (OS) of M1b disease in patients with stage IV NSCLC. METHODS: The study reviewed the medical records and imaging studies of 567 patients with stage IV NSCLC to determine M stage using the 8th edition of TNM staging...
January 29, 2019: Oncologist
https://read.qxmd.com/read/30696723/refining-the-use-of-adjuvant-oxaliplatin-in-clinical-stage-ii-or-iii-rectal-adenocarcinoma
#13
Ofer Margalit, Ronac Mamtani, Scott Kopetz, Yu-Xiao Yang, Yaacov R Lawerence, Samir Abu-Gazala, Kim A Reiss, Talia Golan, Naama Halpern, Dan Aderka, Bruce Giantonio, Einat Shacham-Shmueli, Ben Boursi
BACKGROUND: Current guidelines include the use of adjuvant oxaliplatin in clinical stage II or III rectal adenocarcinoma. However, its efficacy is supported by a single phase II trial. We aimed to examine whether oxaliplatin confers survival benefit in this patient population. METHODS: Using the National Cancer Database (2006-2013) we identified 6,868 individuals with clinical stage II or III rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy...
January 29, 2019: Oncologist
https://read.qxmd.com/read/30696722/bridge-person-centered-collaborative-care-for-patients-with-serious-mental-illness-and-cancer
#14
Kelly E Irwin, Elyse R Park, Lauren E Fields, Amy E Corveleyn, Joseph A Greer, Giselle K Perez, Catherine A Callaway, Jamie M Jacobs, Andrew A Nierenberg, Jennifer S Temel, David P Ryan, William F Pirl
BACKGROUND: Individuals with serious mental illness (SMI) experience increased cancer mortality due to inequities in cancer treatment. Psychiatric care at cancer diagnosis may improve care delivery, yet models for integrating psychiatry and cancer care are lacking. We assessed the feasibility and acceptability of a person-centered collaborative care trial for SMI and cancer. SUBJECTS, MATERIALS, AND METHODS: We developed the Bridge intervention for patients with SMI (schizophrenia, bipolar disorder, and severe major depression) and cancer...
January 29, 2019: Oncologist
https://read.qxmd.com/read/30696721/clinicopathological-and-preclinical-findings-of-nut-carcinoma-a-multicenter-study
#15
Minsun Jung, Soyeon Kim, June-Koo Lee, Sun Och Yoon, Heae Surng Park, Soon Won Hong, Weon-Seo Park, Ji Eun Kim, Joon Kim, Bhumsuk Keam, Hyun Jik Kim, Hyoung Jin Kang, Dong-Wan Kim, Kyeong Cheon Jung, Young Tae Kim, Dae Seog Heo, Tae Min Kim, Yoon Kyung Jeon
BACKGROUND: NUT carcinoma is a rare aggressive disease caused by BRD4/3-NUT fusion, and C-MYC upregulation plays a key role in the pathogenesis. Here, we report on the clinicopathological characteristics of Korean patients with NUT carcinoma and the in vitro efficacy of MYC-targeting agents against patient-derived NUT carcinoma cell lines. MATERIALS AND METHODS: Thirteen patients with NUT carcinoma were evaluated for p53, C-MYC, epidermal growth factor receptor (EGFR), HER2, and programmed cell death ligand 1 (PD-L1) by immunohistochemistry...
January 29, 2019: Oncologist
https://read.qxmd.com/read/30683711/hybrid-capture-based-genomic-profiling-identifies-braf-v600-and-non-v600-alterations-in-melanoma-samples-negative-by-prior-testing
#16
Lise Boussemart, Annie Nelson, Michael Wong, Jeffrey S Ross, Jeffrey Sosman, Janice Mehnert, Gregory Daniels, Kari Kendra, Siraj Mahamed Ali, Vincent A Miller, Alexa B Schrock
BACKGROUND: BRAF and MEK inhibitors are approved for BRAF V600-mutated advanced melanoma, with response rates of up to 70%. Responses to targeted therapies have also been observed for diverse non-V600 BRAF alterations. Thus, sensitive, accurate, and broad detection of BRAF alterations is critical to match patients with available targeted therapies. MATERIALS AND METHODS: Pathology reports were reviewed for 385 consecutive melanoma cases with BRAF mutations or rearrangements identified using a hybrid capture-based next-generation sequencing comprehensive genomic profiling (CGP) assay during the course of clinical care...
January 25, 2019: Oncologist
https://read.qxmd.com/read/30683710/randomized-trial-of-a-tailored-cognitive-behavioral-therapy-mobile-application-for-anxiety-in-patients-with-incurable-cancer
#17
Joseph A Greer, Jamie Jacobs, Nicole Pensak, James J MacDonald, Charn-Xin Fuh, Giselle K Perez, Alina Ward, Colleen Tallen, Alona Muzikansky, Lara Traeger, Frank J Penedo, Areej El-Jawahri, Steven A Safren, William F Pirl, Jennifer S Temel
BACKGROUND: The aim of this study was to test the efficacy of a tailored cognitive-behavioral therapy (CBT) mobile application (app) to treat anxiety in patients with incurable cancer. MATERIALS AND METHODS: Patients with incurable cancers ( n = 145) who reported elevated anxiety symptoms at two cancer centers were randomized to receive either the CBT mobile app for anxiety or a mobile health education program (control) delivered via tablet computers, which patients self-administered over 12 weeks...
January 25, 2019: Oncologist
https://read.qxmd.com/read/30683709/suspected-hereditary-cancer-syndromes-in-young-patients-heterogeneous-clinical-and-genetic-presentation-of-colorectal-cancers
#18
Claudia Maletzki, Maja Hühns, Ingrid Bauer, Friedrich Prall, Christian Junghanss, Larissa Henze
Colorectal cancer (CRC) is rare in young patients without a confirmed family history of cancer. Reports of an increased prevalence of POLD1 / POLE mutations in young patients with colorectal cancer have raised awareness and support routine genetic testing for patients with early-onset tumors. In cases of CRC without proven MMR -germline mutation, molecular analyses are warranted to confirm or rule out other familial CRC syndromes. This article describes the cases of two young male patients, who presented with locally advanced and metastatic CRC, and reports the results of the germline mutational analyses done for both patients...
January 25, 2019: Oncologist
https://read.qxmd.com/read/30679319/carcinoma-of-unknown-primary-with-eml4-alk-fusion-response-to-alk-inhibitors
#19
Peng Zhao, Ling Peng, Wei Wu, Yi Zheng, Weiqin Jiang, Hangyu Zhang, Zhou Tong, Lulu Liu, Ruobing Ma, Liping Wang, Ming Yao, Kai Wang, Weijia Fang, Liming Wu
With the advent of next-generation sequencing (NGS) and precision medicine, investigators have determined that tumors from different tissue sources that have the same types of genetic mutations will have a positive response to the same targeted therapy. This finding has prompted us to seek potential therapeutic targets for patients with carcinoma of unknown primary (CUP) using NGS technology. Here, we reported a case of a woman with CUP resistance to chemotherapy. We detected 450 cancer-related gene alterations using three metastatic tumor specimens and found the presence of EML4 exon13 and ALK exon20 fusion...
January 24, 2019: Oncologist
https://read.qxmd.com/read/30679318/everolimus-plus-exemestane-for-hormone-receptor-positive-advanced-breast-cancer-a-pam50-intrinsic-subtype-analysis-of-bolero-2
#20
Aleix Prat, Jan Christoph Brase, Yuan Cheng, Paolo Nuciforo, Laia Paré, Tomás Pascual, Débora Martínez, Patricia Galván, Maria Vidal, Barbara Adamo, Gabriel N Hortobagyi, José Baselga, Eva Ciruelos
BACKGROUND: The prognostic and predictive value of the two nonluminal (human epidermal growth factor receptor 2 [HER2]-enriched and basal-like) subtypes within advanced hormone receptor-positive (HR+) breast cancer is currently unknown. MATERIALS AND METHODS: This study retrospectively analyzed 261 tumors (80.7% primary; 19.3% metastatic) from the BOLERO-2 study; BOLERO-2 randomized 724 patients with advanced HR+/HER2-negative breast cancer to everolimus plus exemestane or placebo plus exemestane...
January 24, 2019: Oncologist
journal
journal
20207
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"